• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Professional Introduction to 3-Bromo-5-(difluoromethyl)-4-methylpyridine (CAS No. 1805279-69-9)

3-Bromo-5-(difluoromethyl)-4-methylpyridine, identified by its CAS number 1805279-69-9, is a significant compound in the realm of chemical and pharmaceutical research. This heterocyclic aromatic molecule has garnered attention due to its versatile applications in drug discovery and synthetic chemistry. The presence of both bromine and difluoromethyl substituents makes it a valuable intermediate for constructing complex molecular frameworks, particularly in the development of novel therapeutic agents.

The compound's structure, featuring a pyridine core with 3-bromo and 5-(difluoromethyl) functional groups, endows it with unique reactivity that is highly conducive to further chemical modifications. Pyridine derivatives are widely recognized for their biological activity, and the specific substitution pattern of this molecule opens up numerous possibilities for designing molecules with enhanced pharmacological properties.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various disease pathways. Among these, kinase inhibitors have been a major area of interest due to their critical role in regulating cellular signaling cascades. The brominated pyridine derivative mentioned here has shown promise as a scaffold for designing kinase inhibitors. Specifically, the bromine atom at the 3-position allows for further functionalization via cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, which are essential for constructing biaryl structures prevalent in many active pharmaceutical ingredients (APIs).

The difluoromethyl group at the 5-position is another key feature that enhances the compound's utility. Difluoromethylation is a powerful strategy in medicinal chemistry to improve metabolic stability, binding affinity, and overall pharmacokinetic properties of drug candidates. This moiety can be introduced through various synthetic routes, including the use of 1,1-difluoro-2,2-tetramethoxypropane or other difluoromethylating agents, often in conjunction with transition metal catalysts.

Recent studies have highlighted the importance of fluorinated compounds in the development of antiviral and anticancer agents. For instance, pyridine derivatives containing difluoromethyl groups have been reported to exhibit potent activity against viral proteases and kinases. The compound 3-Bromo-5-(difluoromethyl)-4-methylpyridine can serve as a key building block for synthesizing such molecules, offering a flexible platform for structure-activity relationship (SAR) studies.

The methyl group at the 4-position of the pyridine ring also contributes to the compound's chemical diversity. This substituent can influence both electronic and steric properties, allowing researchers to fine-tune the molecule's interactions with biological targets. Additionally, the methyl group provides a handle for further derivatization via alkylation or other organic transformations.

Synthetic methodologies involving this compound have been explored in several recent publications. One notable approach involves a multi-step synthesis starting from commercially available pyridine precursors. The bromination at the 3-position is typically achieved using brominating agents such as N-bromosuccinimide (NBS) or molecular bromine (Br?), often under radical or electrophilic conditions. Subsequent introduction of the difluoromethyl group can be accomplished using palladium-catalyzed cross-coupling reactions with appropriate difluoromethyl halides or boronic acids.

The compound's reactivity also makes it suitable for exploring novel synthetic pathways. For example, it can be used in directed ortho-metalation (DoM) strategies to introduce various functional groups at specific positions of the pyridine ring. This flexibility is particularly valuable in drug discovery pipelines where precise control over molecular architecture is crucial.

In conclusion, 3-Bromo-5-(difluoromethyl)-4-methylpyridine (CAS No. 1805279-69-9) represents a versatile and valuable intermediate in synthetic chemistry and pharmaceutical research. Its unique structural features and reactivity make it an attractive scaffold for developing novel therapeutic agents targeting various diseases. As research continues to uncover new applications for this compound, its importance in drug discovery is likely to grow further.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)